Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.

Karlijn H G RuttenReinier A P RaymakersBouke P C HazenbergHans L A NienhuisEdo Vellenga Monique C Minnema

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2018)

In the 2013-2016 cohort there was a trend toward improved 6-month OS, and an improved haematological response. Patients in this cohort had more advanced cardiac disease and received bortezomib more frequently, but diagnostic delay was similar to the 2008-2012 cohort. For further prognostic improvement, practitioners should be more alert, especially for cardiac amyloidosis.

Keyphrases

newly diagnosed
end stage renal disease
multiple myeloma
left ventricular
ejection fraction
chronic kidney disease
primary care
prognostic factors
peritoneal dialysis
case report
clinical decision support
atrial fibrillation